Navigation Links
Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
Date:10/27/2013

e of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; growth strategies; timing and achievement of product development milestones; outcome of ongoing litigation; the impact and benefits of market development; product introductions; unexpected new data, safety and technical issues; market conditions; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our  recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

[1]  IFR modality is available in CE mark countries and Japan; not commercially available in the United States.


'/>"/>
SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. , ... AGN ), a leading global pharmaceutical company, and Oculeve, ... treatments for dry eye disease, today announced that they ... acquire Oculeve in an all-cash transaction.  Under the terms ... $125 million upfront payment and commercialization milestone payments related ...
(Date:7/6/2015)... /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... its board of directors has received a preliminary non-binding ... Zhang , chairman of the board of directors of ... investment vehicle wholly owned by Mr. Zhang(" Neptunus Holding ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
(Date:7/6/2015)... ... July 06, 2015 , ... Human ... drug discovery. iPSCs are generated from adult cells, such as blood or skin, ... in the human body. , iPSC-derived cardiomyocytes have proven valuable ...
(Date:7/6/2015)... ... 06, 2015 , ... PristineHydro ( http://www.pristinewaterfilters.com ) has developed ... impurities; it also properly mineralizes the water with electrolyte salts.  Common tap water ... contaminants are a byproduct of how the water is treated chemically.  In response, ...
(Date:7/6/2015)... ... 06, 2015 , ... University of Pittsburgh Cancer Institute (UPCI) scientists ... to reflect newly available tests that better incorporate personalized medicine into diagnosing the condition. ... cancer tests is published in the July issue of the scientific journal Thyroid ...
(Date:7/6/2015)... ... ... a report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts ... the U.S. will suffer from thinning hair or hair loss . For these 30 million ... beauty queen, who was interviewed for the report began losing her hair at age 11 due ...
(Date:7/6/2015)... ... 06, 2015 , ... Acara Partners, a leading business team ... its complimentary educational webinar series for the summer of 2015. ... their clients through targeted marketing, sales, digital communications, branding and business development programs. ...
Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3
... new cases of malaria are reported each year. However, ... from Leeds, //with funding from the Bill & Melinda ... protection from the disease. ,Design lecturer Dr ... Xeroshield at the Roslin Biocentre will develop a precisely ...
... in the June issue of the Journal of Family Psychology ... their life// and it is important that the baby's security ... sometimes it's difficult for parents to deal with their child's ... of human and community development. "A mother may become anxious ...
... British Journal of Psychology showed that men find heavier women ... wanted to test their theory linking appetite and sexual preference ... women. ,Dr Viren Swami from Liverpool University's ... University conducted the study among 60 university students. Half ...
... conducted by University of Cincinnati on skin cancers has revealed ... skin cancer, and when they do get //it they are ... diagnosis is usually done at an advanced stage. ... Dermatology by Dr. Hugh Gloster, Dermatologist at University of Cincinnati, ...
... new vehicle for delivering radioactive iodine dose to cure ... ,Synthetic scorpion venom is used as carriers ... trials is successfully complete and was conducted by under ... Center's Maxine Dunitz Neurosurgical Institute. About 18 patients participated ...
... among praying mantids – that is, the female praying ... ,However, the possibility that males may also have something ... resolved experimentally. In a paper in the August issue ... (SUNY-Fredonia), study male risk-taking behavior in a praying mantis ...
Cached Medicine News:Health News:Revolutionary Net To Control Malaria 2Health News:Mother And Child Bond In First Year Of Baby's Life 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: